{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:31:26Z","timestamp":1787070686590,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study\u2019s objective was to assess the adverse events (AEs) of rituximab (RTX) therapy in people with multiple sclerosis (pwMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This observational study was conducted on clinical data of pwMS who visited an MS center in Iran from January 2015 to January 2018 and underwent RTX therapy. The primary efficacy outcomes assessed were disability progression and the annual relapse rate. Initially the patients received 2 g of RTX (Zytux AryoGen Pharmed Company Iran) delivered in four 500-mg doses via an intravenous line each of which took 6 hours to avoid unwanted reactions. Afterward two 500-mg doses of RTX were administered every 6 months. we administered each dose within 4\u20136 hours to minimize unwanted reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 307 RTX-treated patients were included in the study. Around 75.2% of patients were female. The mean (standard deviation (SD)) age was 37.9 (9) years, and the mean (interquartile range (IQR)) disease duration was 7 (7) years. During treatment, the Expanded Disability Status Scale (EDSS) remained unchanged for patients with shorter disease duration (&lt;3 years), and it was significantly improved for patients with longer disease duration (&gt;3 years,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.015). Around 39.4% of the patients had at least one side effect, most of which were minor infections of the urinary and respiratory tract, all mild in nature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>RTX treatment is well-tolerated and safe, with a minor risk of mild infusion reactions and minor side effects for MS patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_366_22","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:00:25Z","timestamp":1751274025000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Adverse Events of Rituximab in Multiple Sclerosis Patients, Isfahan, Iran"],"prefix":"10.4103","volume":"16","author":[{"given":"Ali","family":"Rahimisadegh","sequence":"first","affiliation":[{"name":"Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakiba","family":"Houshi","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Afshari-Safavi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham Moases","family":"Ghaffary","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6]]},"reference":[{"key":"R1-20250825","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1191\/1352458504ms1088oa","article-title":"Resistance training improves strength and functional capacity in persons with multiple sclerosis","volume":"10","author":"White","year":"2004","journal-title":"Mult Scler J"},{"key":"R2-20250825","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ajpath.2018.11.007","article-title":"Expression of bone morphogenetic proteins in multiple sclerosis lesions","volume":"189","author":"Costa","year":"2019","journal-title":"Am J Pathol"},{"key":"R3-20250825","article-title":"McAlpine's multiple sclerosis:Elsevier Health Sciences","author":"McAlpine","year":"2005"},{"key":"R4-20250825","first-page":"59","article-title":"Association of helicobacter pylori with multiple sclerosis:Protective or risk factor?","volume":"19","author":"Mirmosayyeb","year":"2020","journal-title":"Curr J Neurol"},{"key":"R5-20250825","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/jcm9051326","article-title":"Clinical characteristics and disability progression of early-and late-onset multiple sclerosis compared to adult-onset multiple sclerosis","volume":"9","author":"Mirmosayyeb","year":"2020","journal-title":"J Clin Med"},{"key":"R6-20250825","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1212\/NXI.0000000000000309","article-title":"B-cell populations discriminate between pediatric-and adult-onset multiple sclerosis","volume":"4","author":"Schwarz","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R7-20250825","doi-asserted-by":"crossref","first-page":"101419","DOI":"10.1016\/j.msard.2019.101419","article-title":"Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients:An observational study","volume":"36","author":"Moghadasi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"R8-20250825","first-page":"1","article-title":"Rituximab for the treatment of multiple sclerosis:A review","volume":"269","author":"Chisari","year":"2021","journal-title":"J Neurol"},{"key":"R9-20250825","doi-asserted-by":"crossref","first-page":"104729","DOI":"10.1016\/j.msard.2023.104729","article-title":"Current evidence of rituximab in the treatment of multiple sclerosis","volume":"75","author":"Techa-Angkoon","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R10-20250825","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1352458519858604","article-title":"Rituximab treatment for multiple sclerosis","volume":"26","author":"Ineichen","year":"2020","journal-title":"Mult Scler J"},{"key":"R11-20250825","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.4049\/jimmunol.1700822","article-title":"Transient BAFF blockade inhibits type 1 diabetes development in nonobese diabetic mice by enriching immunoregulatory B lymphocytes sensitive to deletion by anti-CD20 cotherapy","volume":"199","author":"Wang","year":"2017","journal-title":"J Immunol"},{"key":"R12-20250825","first-page":"9084759","article-title":"Safety and efficacy of rituximab in multiple sclerosis:A retrospective observational study","author":"Yamout","year":"2018","journal-title":"J Immunol Res 2018"},{"key":"R13-20250825","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"Comparative effectiveness of rituximab relative to IFN-? or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry","volume":"24","author":"Spelman","year":"2018","journal-title":"Mult Scler J"},{"key":"R14-20250825","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R15-20250825","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis:2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"R16-20250825","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R17-20250825","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R18-20250825","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica:A multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J Neurol"},{"key":"R19-20250825","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"R20-20250825","article-title":"A simple guide to IBM SPSS statistics-version 23.0","author":"Kirkpatrick","year":"2015","journal-title":"Cengage Learning"},{"key":"R21-20250825","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"R22-20250825","doi-asserted-by":"crossref","first-page":"102210","DOI":"10.1016\/j.msard.2020.102210","article-title":"Efficacy and safety of rituximab in multiple sclerosis:Experience from a developing country","volume":"43","author":"Mathew","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R23-20250825","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","article-title":"Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis:A systematic review and meta-analysis","volume":"18","author":"Hu","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R24-20250825","doi-asserted-by":"crossref","first-page":"e0190425","DOI":"10.1371\/journal.pone.0190425","article-title":"Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases","volume":"13","author":"Memon","year":"2018","journal-title":"PLoS One"},{"key":"R25-20250825","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden:A rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol"},{"key":"R26-20250825","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s00415-018-8899-3","article-title":"Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis:A hospital-based study","volume":"265","author":"Alcal\u00e1","year":"2018","journal-title":"J Neurol"},{"key":"R27-20250825","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"R28-20250825","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00325481.2019.1649975","article-title":"A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus","volume":"131","author":"Leonidou","year":"2019","journal-title":"Postgrad Med"},{"key":"R29-20250825","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/1352458519872889","article-title":"Treatment of multiple sclerosis with rituximab:A multicentric Italian\u2013Swiss experience","volume":"26","author":"Zecca","year":"2020","journal-title":"Mult Scler J"},{"key":"R30-20250825","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis:A 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"R31-20250825","doi-asserted-by":"crossref","first-page":"577317","DOI":"10.1016\/j.jneuroim.2020.577317","article-title":"Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis:A systematic review and meta-analysis","volume":"347","author":"Tian","year":"2020","journal-title":"J Neuroimmunol"},{"key":"R32-20250825","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"R33-20250825","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder:A prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J Neurol"},{"key":"R34-20250825","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s12031-020-01523-w","article-title":"Effect of rituximab on expanded disability status scale and relapse rate in multiple sclerosis patients","volume":"70","author":"Mazdeh","year":"2020","journal-title":"J Mol Neurosci"},{"key":"R35-20250825","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"R36-20250825","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/1735-1995.200275","article-title":"Efficacy and safety of rituximab in neuromyelitis optica:Review of evidence","volume":"22","author":"Etemadifar","year":"2017","journal-title":"J Res Med Sci"},{"key":"R37-20250825","doi-asserted-by":"crossref","first-page":"e0197415","DOI":"10.1371\/journal.pone.0197415","article-title":"Effectiveness and safety of Rituximab in multiple sclerosis:An observational study from Southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"PLoS One"},{"key":"R38-20250825","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","article-title":"Rituximab add-on therapy for breakthrough relapsing multiple sclerosis:A 52-week phase II trial","volume":"74","author":"Naismith","year":"2010","journal-title":"Neurology"},{"key":"R39-20250825","doi-asserted-by":"crossref","first-page":"103857","DOI":"10.1016\/j.msard.2022.103857","article-title":"Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis:A 5 year prospective cohort study","volume":"63","author":"Bawand","year":"2022","journal-title":"Mult Scler Relat Disord"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_366_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:34:55Z","timestamp":1787067295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_366_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_366_22","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2022-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}